The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

Inclusion Criteria

• •Subjects diagnosed with type 2 diabetes, insulin naïve and treated with metformin as monotherapy for at least 3 months prior to screening, at a stable dose of at least 1500 mg/day or metformin (at least 1500 mg/day) and a sulfonylurea (less than or equal to half of the maximum approved dose), both at a stable dose for at least 3 months prior to screening. Previous short-term insulin treatment in connection with intercurrent illness is allowed at the discretion of the Investigator
• •HbA1c 7.0-10.0% (both inclusive) for subjects on metformin monotherapy
• •HbA1c 7.0-8.5% (both inclusive) for subjects on metformin in combination with a sulphonylurea
• •Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator
• •Impaired kidney function
• •Impaired liver function
• •Uncontrolled treated/untreated hypertension
• •Cancer or any clinically significant disease or disorder as judged by the Investigator
• •Previous participation in the run-in phase of this trial. Re-screening is allowed once
• •History of chronic pancreatitis or idiopathic pancreatitis